Corsi Di Formazione Organizzati Da MSO - ANNO 2016

CORSO: Breast Cancer controversies
This house believes that...

Chieti, 27 June 2016

Direttore: Ettore Cianchetti, Clara Natoli
CREDITI ECM: 6

SCARICA IL PDF...

PROGRAMMA DEL CORSO (CLICCARE SULLE ICONE PER SCARICARE LE SLIDES)
La partecipazione è gratuita.
Le iscrizioni si accettano esclusivamente on line sul sito
del Provider www.strategieonweb.it - pagina ECM 2016
09:45 Registration
10:15 Introduction and Authorities welcome
I session
Moderatori: Corrado Ficorella, L’Aquila & Clara Natoli, Chieti
10:30 THBT Italian breast cancer screening guidelines should be updated Marzia Muzi, Ortona
10:45 Discussion leader: Doralba Morrone, Firenze
11:00 THBT neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm Valentina Guarneri, Padova
11:15 Discussion leader: Antonio Frassoldati, Ferrara
11:30 THBT selected HER2/++ FISH negative breast cancer should be considered as HER2/+++ Domenico Angelucci, Ortona
11:45 Discussion leader: Patrizia Querzoli, Ferrara
12:00 THBT axillary lymph node dissection should be avoided in patients with 1–2 macro-metastatic axillary nodes Ettore Cianchetti, Ortona
12:15 Discussion leader: Mario Taffurelli, Bologna
12:30 THBT hypo-fractionated irradiation and partial breast irradiation are recommended after breast conserving surgery Domenico Genovesi, Chieti
12:45 Discussion leader: Lorenzo Livi, Firenze
13:00 THBT chemoprevention and prophylactic surgery should be offered to healthy women carrying BRCA1/2 mutations Laura Cortesi, Modena
13:15 Discussion leader: Francesco Fanfani, Chieti
13:30 Light lunch
II session
Moderatori: Amedeo Pancotti, Teramo & Carlo Garufi , Pescara
14:30 THBT that fertility should be preserved in young women with early breast cancer Gianmario Tiboni, Ortona
14:45 Discussion leader: Lucio Laudadio, Lanciano
15:00 THBT metronomic chemotherapy has an emerging role for breast cancer treatment Elisabetta Munzone, Milano
15:15 Discussion leader: Vito Lorusso, Bari
15:30 THBT that neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer women Antonino Grassadonia, Chieti
15:45 Discussion leader: Silvana Leo, Lecce
16:00 Coffee break
16:15 THBT endocrine combination therapies are recommended for RE+ HER2- tumors Katia Cannita, L'Aquila
16:30 Discussion leader: Serena Di Cosimo, Milano
III session
Moderatori: Antonio Nuzzo, Lanciano & Clara Natoli, Chieti
16:45 THBT taxanes and bevacizumab are the standard fi rst line therapy for HER2- metastatic breast cancer Luca Moscetti, Modena
17:00 Discussion leader: Giorgio Mustacchi, Trieste
17:15 THBT metastatic triple positive breast cancer needs different therapeutic strategies than HER2-enriched tumors Patrizia Vici, Rome
17:30 Discussion leader: Andrea Michelotti, Pisa
17:45 Conclusions Clara Natoli & Ettore Cianchetti
18:00 Questionario di valutazione dell'apprendimento
18:15 Chiusura dei lavori